

Karl Storz
Endoscopy-America, Inc.

600 Corporate Pointe 5th Floor
Culver City, California 90230-7600
Phone 310 338 8100

Toll Free 800 421 0837
Fax 310 410 5527

K 004037

FEB - 2 2001

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Devices Act (SMDA) of 1990 and 21 CFR 807.92. All data included in this document is accurate and complete to the best of Karl Storz Endoscopy - America's knowledge.

Applicant: Karl Storz Endoscopy – America, Inc.
600 Corporate Pointe
Culver City, CA 90230-7600
(310) 338-8100

Contact: Jennifer S. Portugal
Clinical Affairs Specialist

Device Identification: Common Name
Diagnostic X-Ray
Trade Name
Karl Storz X-Ray System XR-MX

Indication: The X-Ray System XR-MX is intended to detect and localize urinary calculi in lithotripsy procedures.


Device Description:

The Karl Storz X-Ray System XR-MX is a diagnostic imaging system which can be equipped with two different image chains type S and type D. The XR-MX is modular in design for ease of use in lithotripsy procedures featuring fluoroscopy and snapshot imaging. Microprocessor technology simplifies the operation, monitors the system function and displays relevant exposure parameters.

Substantial Equivalence:

Substantial Equivalence is not a requirement of the Simplified Radiology Submission.

Signed:


James Lee, Ph.D.
Regulatory Affairs Specialist



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

FEB - 2 2001

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Jennifer S. Portugal
Regulatory Affairs Specialist
Karl Storz Endoscopy- America, Inc.
600 Corporate Pointe
CULVER CITY CA 90230-7600

Re: K004037
X-Ray System XR-MX
Dated: December 27, 2000
Received: December 28, 2000
Regulatory Class: II
21 CFR §892.1650/Procode: 90 JAA

Dear Ms. Portugal:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for *in vitro* diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Daniel G. Schultz, M.D.
Captain, USPHS
Acting Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure (s)

510(k) Number (if known): Not yet assigned

Device Name: X-Ray System XR-MX

Indications for Use: The X-Ray System XR-MX is intended to detect and localize urinary calculi in lithotripsy procedures.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON
ANOTHER PAGE IF NEEDED).

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use: ✓
(Per 21 CFR 801.109)

OR Over-The-Counter Use: _____

(Optional Format 1-2-96)

Stuart A. Heyman
(Division Sign-Off)

Division of Reproductive, Abdominal, ENT,
and Radiological Devices

510(k) Number K004037

0003